Supravalvular aortic stenosis (SVAS) and Williams Beuren syndrome (WBS) can be considered as inherited diseases affecting the whole arterial tree and causing narrowing of the vessels. It has been reported that abnormal deposition of elastin in arterial walls of patients with SVAS and WBS leads to increased proliferation of arterial smooth muscle cells (SMC), which result in the formation of hyperplastic intimal lesions. In this work, we conducted morphological and morphometrical analysis with stenotic aortas from patients suffering from SVAS and WBS and from healthy control subjects and demonstrated that the amount of elastic fibers and the loss of integrity of vascular elastic fibers in the aortas reflect similar changes in the skin of patients with SVAS or WBS, as reported in our previous work conducted on skin in these pathological states. On the other hand, we conducted investigations on metalloproteinases (MMP2, MMP9, MMP7) and their specific tissue inhibitors TIMP1 and TIMP2 to verify their possible involvement in the etiopathogeny of SVAS and WBS. We particularly evidenced an altered MMP9/TIMP1 balance in favor of matrix degradation which could facilitate SMC migration and neointimal hyperplasia. Our findings suggest that elastinolytic enzymes secreted by arterial SMC, possibly including matrilysin 1, are critical for the development of arterial lesions in SVAS and WBS and contribute to perpetuate arterial stenosis in either SVAS or WBS.

1.
Williams JCP, Barrat-Boyes BG, Lowe JB: Supravalvular aortic stenosis. Circulation 1961;24:1311–1318.
2.
Beuren AJ, Apitz J, Harmjanz O: Supravalvular aortic stenosis in association with mental retardation and a certain facial appearance. Circulation 1962;26:1325–1340.
3.
Eisenberg R, Young D, Jacobson B, Boito A: Familial supravalvular aortic stenosis. Am J Dis Child 1964;108:341–347.
4.
Ewart AK, Morris CA, Atkinson D, Sternes K, Spallone P, Stock AD, Leppert M, Keating MT: Hemizygosity at the elastin locus in a developmental disorder, Williams syndrome. Nat Genet 1993;5:11–16.
5.
Tassabehji M, Metcalfe K, Donnai D, Hurst J, Reardon W, Burch M, Read AP: Elastin: Genomic structure and point mutations in patients with supravalvular aortic stenosis. Hum Mol Genet 1997;6:1029–1036.
6.
Ewart AK, Jin W, Atkinson D, Morris CA, Keating MT: Supravalvular aortic stenosis associated with a deletion disrupting the elastin gene. J Clin Invest 1994;93:1071–1077.
7.
Fryssira H, Palmer R, Hallidie-Smith KA, Taylor J, Donnai D, Reardon W: Fluorescent in situ hybridisation (FISH) for hemizygous deletion at the elastin locus in patients with isolated supravalvular aortic stenosis. J Med Genet 1997;34:306–308.
8.
Li D, Toland AE, Boak BB, Atkinson DL, Ensing GJ, Morris CA, Keating MT: Elastin point mutations cause an obstructive vascular disease, supravalvular aortic stenosis. Hum Mol Genet 1997;6:1021–1028.
9.
Urban Z, Peyrol S, Plauchu H, Zabot MT, Lebwohl M, Schilling K, Green M, Boyd CD, Csiszar K: Elastin gene deletions in Williams syndrome patients result in altered deposition of elastic fibers in skin and a subclinical dermal phenotype. Pediatr Dermatol 2000;17:12–20.
10.
Metcalfe K, Rucka AK, Smoot L, Hofstadler G, Tuzler G, McKeown P, Siu V, Rauch A, Dean J, Dennis N, Ellis I, Reardon W, Cytrynbaum C, Osborne L, Yates JR, Read AP, Donnai D, Tassabehji M: Elastin: Mutational spectrum in supravalvular aortic stenosis. Eur J Hum Genet 2000;8:955–963.
11.
Curren ME, Atkinson DL, Morris CA, Leppert M, Keating MT: The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell (Cambridge) 1993;73:159–168.
12.
von Dadelszen P, Chitayat D, Winsor EJ, Cohen H, MacDonald C, Taylor G, Rose T, Hornberger LK: De novo 46,XX,t(6;7)(q27;q11;23) associated with severe cardiovascular manifestations characteristic of supravalvular aortic stenosis and Williams syndrome. Am J Med Genet 2000;90:270–275.
13.
Francke U: Williams-Beuren syndrome: Genes and mechanisms. Hum Mol Genet 1999;8:1947–1954.
14.
Rein AJ, Preminger TJ, Perry SB, Lock JE, Sanders SP: Generalized arteriopathy in Williams syndrome: An intravascular ultrasound study. J Am Coll Cardiol 1993;21:1727–1730.
15.
O’Connor WN, Davis JB, Geissler R, Cottrill CM, Noonan JA, Todd EP: Supravalvular aortic stenosis: Clinical and pathological observations in six patients. Arch Pathol Lab Med 1985;109:179–185.
16.
Aggoun Y, Sidi D, Levy BI, Lyonnet S, Kachaner J, Bonnet D: Mechanical properties of the common carotid artery in Williams syndrome. Heart 2000;84:290–293.
17.
Urban Z, Riazi S, Seidl TL, Katahira J, Smoot LB, Chitayat D, Boyd CD, Hinek A: Connection between elastin haploinsufficiency and increased cell proliferation in patients with supravalvular aortic stenosis and Williams-Beuren syndrome. Am J Hum Genet 2002;71:30–44.
18.
Christiano AM, Uitto J: Molecular pathology of the elastic fibers. J Invest Dermatol 1994;103:53–57.
19.
Dridi SM, Ghomrasseni S, Bonnet D, Aggoun Y, Vabres P, Bodemer C, Lyonnet S, De Prost Y, Fraitag S, Pellat B, Sidi D, Godeau G: Skin elastic fibers in Williams syndrome. Am J Med Genet 1999;87:134–138.
20.
Ward MR, Pasterkamp G, Yeung AC, Borst C: Arterial remodeling. Mechanisms and clinical implications. Circulation 2000;102:1186–1191.
21.
Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–2503.
22.
Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503–2509.
23.
Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, Stetler-Stevenson WG, Froehlich J, Lakatta EG: Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996;148:121–128.
24.
Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999;274:21491–21494.
25.
Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: Evolution, structure and function. Biochim Biophys Acta 2000;1477:267–283.
26.
Dollery CM, Humphries SE, McClelland A, Latchman DS, McEwan JR: Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999;99:3199–3205.
27.
Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, Bilato C, Gluzband YA, Crow MT, Stetler-Stevenson W, Capogrossi MC: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 1998;98:2195–2201.
28.
Ganter P, Jolles G: Histochimie Normale et Pathologique. Paris, Gauthier-Villars, 1969.
29.
Godeau G, Gonnor G, Jolivet O, Shoeveart D, Pompidou A, Lagrue G, Robert AM: Selective histochemical method for the quantitative estimation of elastic fibers by computerized morphometric analysis. Anal Quant Cytol Histol 1986;4:321–325.
30.
Serra J: Image Analysis and Mathematical Morphology. London, Academic Press, 1982, pp 55–95.
31.
Uitto J, Paul JL, Brockley K, Pearce RH, Clark JG: Elastic fibers in human skin: Quantitation of elastic fibers by computerized digital image analyses and determination of elastin by radioimmunoassay of desmosine. Lab Invest 1983;49:499–505.
32.
Bouissou H, Pieraggi MT, Julian M, Douste-Blazy L: Cutaneous aging. Its relation with atheriosclerosis and atheroma; in Robert L (ed): Frontiers of Matrix Biology. Basel, Karger, 1976, pp 190–211.
33.
Gogly B, Godeau G, Septier D, Hornebeck W, Pellat B, Jeandel C: Measurement of the amounts of elastic fibers in the skin and temporal arteries of healthy aged individuals by automated image analysis. Gerontology 1998;44:318–323.
34.
Holbrook KA, Byers PH: Skin is a window on heritable disorders of connective tissue. Am J Med Genet 1989;34:105–121.
35.
Perou ML: Congenital supravalvular aortic stenosis. A morphological study with attempt at classification. Arch Pathol Lab Med 1961;71:453–466.
36.
Li D, Faury G, Taylor DG, Davis EC, Boyle WA, Mecham RP, Stenzel P, Boak B, Keating MT: Novel arterial pathology in mice and humans hemizygous for elastin. J Clin Invest 1998;102:1783–1787.
37.
Li D, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating MT: Elastin is an essential determinant of arterial morphogenesis. Nature 1998;393:276–280.
38.
Cho A, Reidy MA: Matrix metalloproteinase 9 is necessary for regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002;9:845–855.
39.
Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: Detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995;9:974–980.
40.
Emonard H, Hornebeck W: Binding of 92 kDa and 72 kDa progelatinases to insoluble elastin modulates their proteolytic activation. Biol Chem 1997;378:265–271.
41.
Johnson C, Galis ZS: Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 2004;24:54–60.
42.
Woessner JF Jr: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145–2154.
43.
Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem 1997;378:151–160.
44.
Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, Itohara S, Iguchi A: Deficiency of gelatinase A suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003;108:1375–1381.
45.
Bendeck MP, Conte M, Zhang M, Nili N, Strauss BH, Farwell SM: Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol 2002;160:1089–1095.
46.
Maeda K, Kuzuya M, Cheng XM, Asai T, Kanda S, Tamaya-Mori N, Sasaki T, Shibata T, Iguchi A: Green tea catechins inhibit the cultured smooth muscle cell invasion through the basement barrier. Atherosclerosis 2003;166:23–30.
47.
Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancers: Trials and tribulations. Science 2002;295:2387–2392.
48.
Jacob MP: Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 2003;57:195–202.
49.
Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, Angles-Canu E, Michel JB: Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysm. Am J Pathol 2002;161:1701–1710.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.